Overview

Spectrum of Peripheral and Autonomic Neuropathies in Patients With wtATTR Amyloidosis and Response to Patisiran Therapy"

Status:
Not yet recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of patisiran in patients with wtATTR amyloidosis and symptomatic polyneuropathy by evaluating the effect on neurologic impairment and quality of life.

Phase:

Early Phase 1

Details

Lead Sponsor:

Austin Neuromuscular Center

Collaborator:

Alnylam Pharmaceuticals